The effect of dopamine drugs on reward discounting: A systematic review & meta-analysis
James Meade1, Lucy Greenwald1, Katlyn Hurst1, Jaime J. Castrellon1,2, Gregory R. Samanez-Larkin1,2
1Center for Cognitive Neuroscience, 2Department of Psychology, Duke University

Introduction
Although numerous studies have suggested that pharmacological alteration of the dopamine system alters reward discounting, these studies have yielded inconsistent findings. Here, we conducted a pre-registered systematic review and meta-analysis to evaluate dopaminergic drug-mediated effects on reward discounting of time delays, probabilities, and physical effort requirements in studies of healthy humans, non-human primates, and rodents.

Methods
Studies were identified using PubMed. We limited studies to healthy animals excluding effects in human patient groups or animal models of human disorders. This produced a total of 1,343 articles to screen for inclusion/exclusion. Using random-effects with maximum-likelihood estimation, we meta-analyzed placebo-controlled drug effects for (1) DAT, (2) D1-like agonists, (3) D1-like antagonists, (4) D2-like agonists, and (5) D2-like antagonists.

Results
From 1,343 studies, we meta-analyzed 119 studies testing the impact of DA drugs on reward discounting behavior.

Conclusions
These findings suggest a nuanced relationship between dopamine and discounting behavior and urge caution when drawing generalizations about dopamine-mediated effects on reward-based decision making. Future analyses will test interactions with cost type (time, probability, and effort).